Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) currently has a daily average trading volume of 1.88M but it saw 864429 shares traded on Thursday. With a market cap of 92.49M USD, stock’s current market price of $2.21 came rising about 9.41 while comparing to the previous closing price of $2.02. In past 52 weeks, the stock remained buoying in the range of price level as high as $13.73 and as low as $1.81. In the recent trading on the day, stock has struck highest price mark of $2.23 while lowest mark touched by it was $2.02.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
Taking a look at 20-day trading activity of Oramed Pharmaceuticals Inc. (ORMP) gives us an average price of $2.11, while its current price level is -83.90% below from 52-week high level whereas it is 22.10% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $3.21 while that of 200 days or SMA-200 reads an average of $6.39. A closer look into the stock’s movement over the week reveals that its volatility is standing at 7.84% during that period while stretching the period over a month that decreases to 5.47%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 42.77 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Canaccord Genuity which downgraded the stock as “Hold” in its note to investors issued on January 12, 2023, recommending a price target of between $30 and $3 for it. Canaccord Genuity issued its recommendations for the stock as it initiated the price target for the stock is $27.
Over the week, ORMP’s stock price is moving 7.80% up while it is -0.90% when we observe its performance for the past one month. Year-to-date it is -81.63% down and over the past year, the stock is showing a downside performance of -75.08%.
The latest quarterly earnings report issued by the company was for quarter ended 9/29/2022, when its quarterly earnings per share (EPS) of -$0.18 beat the consensus estimate of -$0.25 for the same. In next quarter, company is expected to be making quarterly sales of $2.95 million as analysts are expecting the sales for current fiscal year at $2.95 million and seeing the company making $56.77 million in sales next year. Moreover, analysts are in estimates of $2.95 million for current-quarter revenue.
Currently, Oramed Pharmaceuticals Inc.’s total number of outstanding shares is 39.42M with 5.26% of that held by the insiders while 11.25% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -26.80% and return on equity (ROE) at -23.50%. Stock’s beta reads 1.82. Stock has a price to book (P/B) ratio of 0.57 while price to sale or P/S ratio amounts to 34.26. Its return on asset (ROA) is -22.10% on average.
A filing at the U.S. Securities and Exchange Commission revealed that KSM ETF came shrinking its share ownership by -1.29% in the Oramed Pharmaceuticals Inc. (ORMP) decreasing its stake to 0.22% with control over 1111.0 shares in the company.
